About: http://data.cimple.eu/news-article/0b1defb71bb341dab8a5c87bcca73674ab9c6b854f0069cacc6db838

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/0b1defb71bb341dab8a5c87bcca73674ab9c6b854f0069cacc6db838 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US biotech firm Novavax on Monday said it had positive results from preclinical studies of a shot combining its influenza and Covid vaccine candidates. The company said a study, which it has posted to a preprint server and will now undergo peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters. "Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu," said Gregory Glenn, the company's president of R&D. The new vaccine combines NanoFlu and NVX-CoV2373, which are separately in late-stage human trials. Neither have yet been approved. Hamsters that were vaccinated and then deliberately infected with the coronavirus retained their body weight compared to those that received a placebo. Lung samples taken from the immunized animals after they were put down showed they were Covid-free. NVX-CoV2373, the company's Covid vaccine candidate, demonstrated 100 percent protection against severe disease in a Phase 3 clinical trial in the United Kingdom, with 89.7 percent efficacy against any form of disease. NVX-CoV2373 uses a piece of the SARS-CoV-2 virus called the spike protein, which the company mass produces inside insect cells. It packages the spike inside nanoparticles and delivers these to the immune system, which trains the host in case they encounter the real virus. The vaccine contains a substance called an adjuvant to deliver a stronger signal to the immune system to respond. NanoFlu is based on similar principles but instead of the spike protein, it presents hemagglutinin -- a protein on the outside of the influenza virus -- to the immune system. ia/jm
schema:headline	Novavax developing combination flu, Covid vaccine
schema:mentions	Gregory of Nazianzus the Elder Novavax Research and development Preprint Nanoparticle Clinical trial Insect Web server Placebo Protein Public health Antibody Ia (cuneiform) Immune system Influenza Pandemic Virus Coronavirus disease United Kingdom Vaccine Coronavirus Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Hemagglutinin Immunologic adjuvant
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-10 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software